Adeel Khan, MD
Pulmonary Disease · Washington, MONPI 1790993863
Payments from drug & device makers
Across 811 payments — averaging $389.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$295K
- Boehringer Ingelheim$6K
- Mylan Specialty L.p.$5K
- Intuitive Surgical$4K
- AstraZeneca$2K
- Viiv Healthcare Company$600
- plus $4K from 37 others
What the payments were for
- Consulting fees$1750%
- Speaking & faculty fees$288,63191%
- Travel & lodging$13,9424%
- Food & beverage$13,1294%
- Education$2170%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$120,413
- NUCALA$61,960
- AREXVY$61,906
- ANORO$19,745
- ANORO ELLIPTA$10,909
- Yupelri$5,050
- Da Vinci Surgical System$3,696
- BREZTRI$833
- TEZSPIRE$833
- FASENRA$833
- AIRSUPRA$684
- Inspire$119
How this compares
$316,111 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 771 | $654,076 |
| OfevNintedanib Esylate | 22 | $305,499 |
| ZemairaAlpha-1-Proteinase Inhibitor | 13 | $143,109 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 209 | $128,534 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $125,697 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 128 | $116,337 |
| Breo ElliptaFluticasone/Vilanterol | 179 | $84,736 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 95 | $51,498 |
| Spiriva HandihalerTiotropium Bromide | 59 | $47,979 |
| Spiriva RespimatTiotropium Bromide | 63 | $45,652 |
| SymbicortBudesonide/Formoterol Fumarate | 129 | $37,546 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 74 | $21,456 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 151 | $18,943 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 73 | $18,579 |
| Incruse ElliptaUmeclidinium Bromide | 45 | $17,967 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta | $294,674 | $907,2041,288 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $5,725 | $409,719192 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $2,250 | $164,816283 claims |
| Grifols USA, LLCProlastin C | $194 | $125,69713 claims |
| Johnson & JohnsonXarelto | $22 | $10,06614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Washington
- Umer SiddiquiWashington$139K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
- Jeffrey HarrisSaint Louis$1.1M
- Kaharu SuminoSaint Louis$1.1M
- Tonya RussellSaint Louis$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.